S
Silvio E. Inzucchi
Researcher at Yale University
Publications - 511
Citations - 64889
Silvio E. Inzucchi is an academic researcher from Yale University. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 92, co-authored 424 publications receiving 54101 citations. Previous affiliations of Silvio E. Inzucchi include University of Toronto & American Diabetes Association.
Papers
More filters
Journal ArticleDOI
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER.
Senthil Selvaraj,Muthiah Vaduganathan,Brian Claggett,Zi Michael Miao,James C. Fang,Orly Vardeny,Akshay S. Desai,Carolyn S.P. Lam,Felipe Martinez,Silvio E. Inzucchi,W. De Boer,Magnus Petersson,Anna Maria Langkilde,John J.V. McMurray,Scott D. Solomon +14 more
TL;DR: In this article , the authors examined the interplay between systolic blood pressure (SBP) and treatment effects of dapagliflozin on SBP and cardiovascular outcomes and found that the beneficial effects were not accounted for the changes in SBP.
Journal ArticleDOI
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout
Jawad H. Butt,Kieran F. Docherty,Brian Claggett,Akshay S. Desai,Magnus Petersson,Anna Maria Langkilde,W. De Boer,Adrian F. Hernandez,Silvio E. Inzucchi,Mikhail Kosiborod,Lars Køber,Carolyn S.P. Lam,Felipe Martinez,Piotr Ponikowski,Marc S. Sabatine,Muthiah Vaduganathan,Pardeep S. Jhund,Scott D. Solomon,John J.V. McMurray +18 more
TL;DR: In this paper , a post hoc analysis of two randomized clinical trials analyzes data for patients with heart failure and with and without gout to gauge the effects of dapagliflozin on the risk of clinical outcomes and the new use of uric acid-lowering agents and colchicine.
Journal ArticleDOI
Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial).
Mikkel Jürgens,Morten Schou,Philip Hasbak,Andreas Kjaer,Emil Wolsk,Bo Zerahn,Mikkel Wiberg,Niels Høgh Brandt,Peter Gæde,Peter Rossing,Jens Faber,Silvio E. Inzucchi,Finn Gustafsson,Caroline Kistorp +13 more
TL;DR: This study was designed to investigate the effects of the SGLT-2 inhibitor empagliflozin on myocardial perfusion and function in patients with T2D and high CVD risk and to submit the results to international peer-reviewed journals and be presented at conferences.
Journal ArticleDOI
Implications of the EMPA-REG Trial for Clinical Care and Research.
TL;DR: This landmark study had several important findings, including striking reductions in the incidence of CV death and heart failure hospitalization and in the progression of renal dysfunction.
Journal ArticleDOI
Hypoglycemia in type 2 diabetes: understanding patients' and physicians' knowledge and experience.
Simon J. Fisher,Xingyue Huang,Manjiri Pawaskar,Edward A. Witt,Swapnil Rajpathak,R. Ravi Shankar,Silvio E. Inzucchi +6 more
TL;DR: Insulin-based antihyperglycemic regimens were associated with high prevalence, severity, familiarity, and fear of hypoglycemia and continued physician education regarding this acute complication of diabetes treatment should be prioritized for those managing patients with T2DM.